Teva Pharmaceutical Industries (NYSE:TEVA) Hits New 12-Month High – Time to Buy?

Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s share price reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $22.17 and last traded at $22.16, with a volume of 5554103 shares changing hands. The stock had previously closed at $22.09.

Analyst Upgrades and Downgrades

TEVA has been the topic of a number of analyst reports. Barclays upped their price target on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a research report on Wednesday, December 18th. UBS Group upped their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. JPMorgan Chase & Co. raised their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. Finally, StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $20.88.

Teva Pharmaceutical Industries Stock Up 0.4 %

The company has a market capitalization of $25.13 billion, a P/E ratio of -26.09, a PEG ratio of 0.99 and a beta of 0.79. The stock has a 50 day moving average price of $17.79 and a 200 day moving average price of $17.52. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89.

Insider Activity

In related news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.55% of the company’s stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of large investors have recently modified their holdings of the company. UMB Bank n.a. raised its position in Teva Pharmaceutical Industries by 555.6% in the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after purchasing an additional 2,067 shares during the period. Smithfield Trust Co grew its holdings in Teva Pharmaceutical Industries by 55.7% in the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after acquiring an additional 980 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter worth approximately $50,000. Claro Advisors LLC purchased a new stake in Teva Pharmaceutical Industries in the third quarter worth $52,000. Finally, Mark Sheptoff Financial Planning LLC purchased a new position in Teva Pharmaceutical Industries during the 2nd quarter valued at $57,000. 54.05% of the stock is currently owned by institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.